Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fish oil therapy in IgA nephropathy

S M Fung1, M J Ferrill, L L Norton

  • 1Department of Pharmacy Practice, School of Pharmacy, University of the Pacific, Stockton, CA, USA.

The Annals of Pharmacotherapy
|January 1, 1997
PubMed
Summary

Fish oil may slow IgA nephropathy progression. This therapy, with few adverse effects, should be considered for patients with IgA nephropathy, given the disease

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of the INNO-LIA syphilis score assay in the resolution of discordant positive screening enzyme immunoassay results for the serological diagnosis of syphilis.

International journal of STD & AIDS·2013
Same author

Comparative evaluation of the INNO-LIA syphilis score and the MarDx Treponema pallidum immunoglobulin G Marblot test assays for the serological diagnosis of syphilis.

International journal of STD & AIDS·2010
Same author

Treatment of bulimia nervosa with ondansetron.

The Annals of pharmacotherapy·2001
Same author

Statin-fibrate combination therapy.

The Annals of pharmacotherapy·2001
Same author

Abciximab vials as multidose containers.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1998
Same author

Drosophila myb is required for the G2/M transition and maintenance of diploidy.

Genes & development·1998

Area of Science:

  • Nephrology
  • Immunology
  • Dietary Supplements

Background:

  • IgA nephropathy (IgAN) is a progressive kidney disease often leading to end-stage renal failure over years.
  • Optimal long-term therapy for IgAN remains unestablished, with treatments like prednisone showing inconsistent efficacy and adverse effects.
  • Previous studies on fish oil for IgAN yielded conflicting results, necessitating further investigation into its long-term safety and efficacy.

Purpose of the Study:

  • To evaluate the potential of fish oil as a safe and effective long-term therapy for slowing IgA nephropathy progression.
  • To address limitations in existing studies, including short durations, small sample sizes, and lack of control groups.

Main Methods:

  • Review and analysis of existing clinical studies on fish oil treatment for IgA nephropathy.
  • Assessment of efficacy, long-term effects, and safety profiles of fish oil in IgAN patients.
  • Consideration of dosage (6-12 g/d) and monitoring requirements.

Main Results:

  • Recent studies suggest fish oil therapy shows promise for slowing IgA nephropathy progression over periods up to 2 years.
  • Fish oil exhibits a low incidence of adverse effects, indicating a favorable safety profile compared to other treatments.
  • Conflicting early results were noted, but newer evidence supports potential benefits.

Conclusions:

  • Fish oil, a safe food supplement, may be a viable option for slowing renal failure progression in IgA nephropathy.
  • Treatment with 6-12 g/d of fish oil should be considered for IgAN patients, alongside regular monitoring of renal function.
  • Further long-term studies are warranted to definitively establish the role of fish oil in IgAN management.

Related Experiment Videos